IONSNasdaqPharmaceutical PreparationsFiscal year ends December 31
IONIS PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$44.38+1.44 (+3.35%)
Close on Oct 19, 2026
- Market cap
- $7.34B
- P/E (TTM)
- –
- Dividend yield
- –
Ionis Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $7.38B | $197.05M |
| Enterprise Value | $5.32B | $106.56M |
| PS Ratio | 8.44 | 3.93 |
| PB Ratio | 16.77 | 2.14 |
| P/TBV Ratio | 16.77 | 2.46 |
Enterprise value
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 6.09 | 2.69 |
Income (trailing twelve months)
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $874.09M | $57.94M |
| Gross Profit | $858.07M | $90.47M |
| Operating Income | -$594.36M | -$21.44M |
| Pretax Income | -$562.00M | -$14.45M |
| Net Income | -$565.17M | -$22.46M |
| EBITDA | -$594.36M | -$16.91M |
| EPS (Diluted) | -$3.46 | -$0.83 |
Margins
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 98.2% | 52.3% |
| Operating Margin | -68.0% | -44.5% |
| Pretax Margin | -64.3% | -13.0% |
| Profit Margin | -64.7% | -39.2% |
| EBITDA Margin | -68.0% | -31.3% |
| FCF Margin | -64.2% | -8.85% |
Returns
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -105.5% | -53.1% |
| Return on Assets (ROA) | -18.9% | -41.0% |
| Return on Capital Employed (ROCE) | -22.2% | -37.8% |
Growth
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -7.41% | 6.01% |
| Revenue Growth (3Y CAGR) | 17.1% | 2.25% |
| Revenue Growth (5Y CAGR) | 5.29% | 6.42% |
Balance sheet
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.05B | $62.42M |
| Net Cash (Debt) | $2.05B | $15.68M |
| Net Cash Per Share | $12.36 | $0.65 |
| Equity (Book Value) | $439.74M | $48.79M |
| Book Value Per Share | $2.65 | $1.36 |
| Tangible Book Value | $439.74M | $23.06M |
| Working Capital | $2.18B | $75.77M |
Financial position
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 7.89 | 3.30 |
| Quick Ratio | 6.51 | 2.39 |
| Interest Coverage | -31.58 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$496.43M | -$12.35M |
| Capital Expenditures | -$64.41M | -$1.06M |
| Free Cash Flow | -$560.84M | -$20.28M |
| FCF Per Share | -$3.37 | -$0.41 |
Efficiency
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.29 | 0.38 |
| Inventory Turnover | 0.54 | 2.67 |
| Revenue Per Employee | $623.46K | $398.96K |
| Profits Per Employee | -$403.12K | -$732.08K |
| Employee Count | 1,402 | 73 |
Dividends and yields
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -7.66% | -21.2% |
| FCF Yield | -7.60% | -7.64% |
Shares
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 166,184,000 | 59,128,900 |
| Shares Change (YoY) | 0.75% | 11.1% |
| Shares Change (QoQ) | -0.16% | 0.54% |
| Float | 164,850,000 | 48,744,500 |
| Shares Held by Insiders | 0.80% | 11.8% |
| Shares Held by Institutions | 108.2% | 59.4% |
Taxes
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $3.17M | $91.50K |
Scores
| Measure | Ionis Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 0.91 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Ionis Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.